All In Biotech

Drug Trial Radar · NCT07407283

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

A Multicenter, Open-label, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of SHR-4394 in Combination With Anti-tumor Therapy in Participants With Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Apr 8, 2026

Primary completion

Nov 2027

Study completion Apr 2028

Sponsor

Sponsor type
Industry
First posted
Feb 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to assess the safety and tolerability of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer, and determine the recommended Phase II dose (RP2D); To evaluate of the efficacy of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer based on Prostate-Specific Antigen (PSA) response rate.

Conditions

  • Prostate Cancer

Interventions

  • SHR-4394Drug

    SHR-4394.

  • RezvilutamideDrug

    Rezvilutamide tablets.

  • HRS-5041 TabletsDrug

    HRS-5041 tablets.

  • TazemetostatDrug

    Tazemetostat tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (RP2D) of SHR-4394 combined with anti-tumor therapy in prostate cancer participantsTime frame: About 12 months.
  2. The incidence and severity of adverse events (AEs)Time frame: About 12 months.
  3. Prostate-Specific Antigen response rate (PSA50)Time frame: About 16 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.